NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

You linked me to an accurate trial summary. The excerpt pasted below captures what I think you’re trying to say:

According to overall results, the 331-patient trial
has met the primary endpoint of overall survival
(OS) in newly diagnosed GBM patients after the
progression-free survival (PFS) the initial primary
endpoint of the trial, was found to be unviable.
OS is the "gold standard" for measuring the
clinical benefits of a cancer drug.

The global trial has also reached the secondary
endpoint of OS in recurrent GBM with statistical
significance.

OS is the "gold standard" for measuring the
clinical benefits of a cancer drug.
The global trial has also reached the secondary
endpoint of OS in recurrent GBM with statistical
significance.

In terms of safety, there were five instances of
serious adverse events after the administration
of 2.193 doses of DCVax-L. There were no
reports of autoimmune reactions or incidences
of cytokine storm, according to the presentation.

https://virtualtrials.org/dcvax.cfm